{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:20:22Z","timestamp":1779146422103,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"DOI":"10.7759\/cureus.76061","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:01:02Z","timestamp":1734692462000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India"],"prefix":"10.7759","author":[{"given":"Kaushal","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipulkumar","family":"Thummar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_111_18","article-title":"Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer","volume":"7","author":"Bahl A","year":"2018","unstructured":"Bahl A, Singh R, Wadhwa J, et al.. Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. South Asian J Cancer. 2018, 7:102-5. 10.4103\/sajc.sajc_111_18","journal-title":"South Asian J Cancer"},{"key":"ref2","article-title":"Breast Cancer","author":"Orrantia-Borunda E","year":"2022","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, et al.. Breast Cancer. Exon Publications, Brisbane, Australia; 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02287-x","article-title":"Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers","volume":"129","author":"Bergeron A","year":"2023","unstructured":"Bergeron A, Bertaut A, Beltjens F, et al.. Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers. Br J Cancer. 2023, 129:122-34. 10.1038\/s41416-023-02287-x","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.11.006","article-title":"Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of Ujvira (ZRC-3256, trastuzumab emtansine) with the Kadcyla (trastuzumab emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India","volume":"22","author":"Chiradoni Thungappa S","year":"2022","unstructured":"Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S, Parmar D. Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of Ujvira (ZRC-3256, trastuzumab emtansine) with the Kadcyla (trastuzumab emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India. Clin Breast Cancer. 2022, 22:300-7. 10.1016\/j.clbc.2021.11.006","journal-title":"Clin Breast Cancer"},{"key":"ref5","unstructured":"Cardiotoxicity. An unexpected consequence of HER2-targeted therapies. Accessed: July 26, 2024: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2016\/06\/06\/09\/32\/cardiotoxicity."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184522","article-title":"Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies","volume":"15","author":"Tapia M","year":"2023","unstructured":"Tapia M, Hernando C, Mart\u00ednez MT, et al.. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel). 2023, 15:10.3390\/cancers15184522","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1165781","article-title":"Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers","volume":"10","author":"Zheng Y","year":"2023","unstructured":"Zheng Y, Zou J, Sun C, Peng F, Peng C. Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers. Front Mol Biosci. 2023, 10:1165781. 10.3389\/fmolb.2023.1165781","journal-title":"Front Mol Biosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter FW","year":"2020","unstructured":"Hunter FW, Barker HR, Lipert B, et al.. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020, 122:603-12. 10.1038\/s41416-019-0635-y","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin S","year":"2022","unstructured":"Jin S, Sun Y, Liang X, et al.. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022, 7:39. 10.1038\/s41392-021-00868-x","journal-title":"Signal Transduct Target Ther"},{"key":"ref10","unstructured":"Trastuzumab emtansine - an overview. (2024). https.\/\/www.sciencedirect.com\/topics\/neuroscience\/trastuzumab-emtansine."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul P","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020, 18:3-19. 10.1158\/1541-7786.MCR-19-0582","journal-title":"Mol Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde L","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018, 35:1763-74. 10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.206","article-title":"Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: outcomes from a single center retrospective study in India","volume":"34","author":"Patel KB","year":"2023","unstructured":"Patel KB. Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: outcomes from a single center retrospective study in India. Ann Oncol. 2023, 34:S1493.","journal-title":"Ann Oncol"},{"key":"ref14","unstructured":"India breast meeting. (2024). https.\/\/www.indiabreastmeeting2024.com\/."},{"key":"ref15","unstructured":"ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale - ECOG-ACRIN Cancer Research Group. (2024). https.\/\/ecog-acrin.org\/resources\/ecog-performance-status\/."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1287253","article-title":"Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment","volume":"13","author":"Houvenaeghel G","year":"2023","unstructured":"Houvenaeghel G, Cohen M, Gon\u00e7alves A, et al.. Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment. Front Oncol. 2023, 13:1287253. 10.3389\/fonc.2023.1287253","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/path.4288","article-title":"Metastatic progression of breast cancer: insights from 50 years of autopsies","volume":"232","author":"Cummings MC","year":"2014","unstructured":"Cummings MC, Simpson PT, Reid LE, et al.. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014, 232:23-31. 10.1002\/path.4288","journal-title":"J Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop IE","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, et al.. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017, 18:743-54. 10.1016\/S1470-2045(17)30313-3","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606)","volume":"31","author":"Montemurro F","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, et al.. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann Oncol. 2020, 31:1350-8. 10.1016\/j.annonc.2020.06.020","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100256","article-title":"How we treat HER2-positive brain metastases","volume":"6","author":"Stavrou E","year":"2021","unstructured":"Stavrou E, Winer EP, Lin NU. How we treat HER2-positive brain metastases. ESMO Open. 2021, 6:100256. 10.1016\/j.esmoop.2021.100256","journal-title":"ESMO Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz G","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al.. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019, 380:617-28. 10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/318832-evaluation-of-the-safety-and-efficacy-of-trastuzumab-emtansine-t-dm1-biosimilar-in-human-epidermal-growth-factor-receptor-2-her2-positive-breast-cancer-findings-from-a-single-center-retrospective-analysis-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:01:08Z","timestamp":1734692468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/318832-evaluation-of-the-safety-and-efficacy-of-trastuzumab-emtansine-t-dm1-biosimilar-in-human-epidermal-growth-factor-receptor-2-her2-positive-breast-cancer-findings-from-a-single-center-retrospective-analysis-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.76061","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}